BillionToOne, Inc. is disrupting molecular diagnostics, leveraging proprietary smNGS technology for rapid growth and a $5.2B market cap. I rate BLLN stock as Buy. - BillionToOne, Inc. is disrupting molecular diagnostics, leveraging proprietary smNGS technology for rapid growth and a $5.2B market cap.
UBS analyst Josh Silverstein maintained a Buy rating on TechnipFMC yesterday and set a price target of $89.00. Silverstein covers the Energy sector, focusing on stocks such as Baker Hughes Company, Halliburton, and SLB. According to TipRanks, Silverstein has an average…
/PRNewswire/ -- Nova Biomedical today announced a transaction involving certain assets of NanoCellect, a provider of microfluidic cell sorting technology. This... WALTHAM, Mass., July 24, 2026 /PRNewswire/ -- Nova Biomedical today announced a transaction involving certain assets of NanoCellect, a provider of microfluidic cell…
Per management, the strong response to Atera and the breadth of studies being planned reinforce its potential to transform biological research. The company believes Atera can help researchers overcome biological complexity, accelerate disease understanding and support the development of better…
Leader Capital Markets analyst Sabina Levi maintained a Buy rating on Teva yesterday and set a price target of ILA15,350.00. The company’s shares closed yesterday at ILA12,630.00. According to TipRanks, Levi is a 4-star analyst with an average return of 45.5% and an 87.50% success…
In a report released yesterday, Louise Chen from Scotiabank maintained a Buy rating on Teva, with a price target of $47.00. The company’s shares closed yesterday at ILA12,630.00. Chen covers the Healthcare sector, focusing on stocks such as Johnson & Johnson, Merck & Company,…
How Much Are You Paying For Tempus AI’s Sales? At the October 27 close, you were paying 9.1 times Tempus AI’s revenue for the twelve months to June 2026, compared with 7.3 times on that same revenue at the end of June. Sales serve…
TempusDirect, a technology-enabled provider of third-party claims cost containment solutions serving the property and casualty ("P&C") insurance industry, today announced a strategic investment from Aldrich Capital Partners ("ACP"), a private equity firm focused on investing in technology-driven business services…
The event will provide an overview of GraftAssure, currently under review by the FDA to be commercialized in kitted form for labs to test patients for kidney transplant rejection. Dr. Liebo will discuss how a kitted GraftAssure test (GraftAssureDx) can…
xR detects gene rearrangements and specific splice variants in solid tumor tissue to support clinical management. Tempus said the IVDR certification supports continued access to xR in the EU beyond 2028, the transition deadline for eligible legacy Class C devices, and…
Companies selling to labs and clinics - Illumina, Thermo Fisher, Danaher, Agilent, 10x Genomics, Qiagen, Exact Sciences, Grail - their results, launches and deals.
An article joins this feed when it matches these terms. Each one is also a search of its own.